Large-Scale Forest Inventories Of The United States And China Reveal Positive Effects Of Biodiversity On Productivity

Background With the loss of species worldwide due to anthropogenic factors, especially in forested ecosystems, it has become more urgent than ever to understand the biodiversity-ecosystem functioning relationship (BEFR). BEFR research in forested ecosystems is very limited and thus studies that incorporate greater geographic coverage and structural complexity are needed. Methods We compiled ground-measured data from approx. one half million forest inventory sample plots across the contiguous United States, Alaska, and northeastern China to map tree species richness, forest stocking, and productivity at a continental scale. Based on these data, we investigated the relationship between forest productivity and tree species diversity, using a multiple regression analysis and a non-parametric approach to account for spatial autocorrelation. Results In general, forests in the eastern United States consisted of more tree species than any other regions in the country. The highest forest stocking values over the entire study area were concentrated in the western United States and Central Appalachia. Overall, 96.4 % of sample plots (477,281) showed a significant positive effect of species richness on site productivity, and only 3.6 % (17,349) had an insignificant or negative effect. Conclusions The large number of ground-measured plots, as well as the magnitude of geographic scale, rendered overwhelming evidence in support of a positive BEFR. This empirical evidence provides insights to forest management and biological conservation across different types of forested ecosystems. Forest timber productivity may be impaired by the loss of species in forests, and biological conservation, due to its potential benefits on maintaining species richness and productivity, can have profound impacts on the functioning and services of forested ecosystems

Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis

BACKGROUND Two phase 3 trials (UNCOVER-2 and UNCOVER-3) showed that at 12 weeks of treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to placebo and etanercept in the treatment of moderate-to-severe psoriasis. We report the 60-week data from the UNCOVER-2 and UNCOVER-3 trials, as well as 12-week and 60-week data from a third phase 3 trial, UNCOVER-1. METHODS We randomly assigned 1296 patients in the UNCOVER-1 trial, 1224 patients in the UNCOVER-2 trial, and 1346 patients in the UNCOVER-3 trial to receive subcutaneous injections of placebo (placebo group), 80 mg of ixekizumab every 2 weeks after a starting dose of 160 mg (2-wk dosing group), or 80 mg of ixekizumab every 4 weeks after a starting dose of 160 mg (4-wk dosing group). Additional cohorts in the UNCOVER-2 and UNCOVER-3 trials were randomly assigned to receive 50 mg of etanercept twice weekly. At week 12 in the UNCOVER-3 trial, the patients entered a long-term extension period during which they received 80 mg of ixekizumab every 4 weeks through week 60; at week 12 in the UNCOVER-1 and UNCOVER-2 trials, the patients who had a response to ixekizumab (defined as a static Physicians Global Assessment [sPGA] score of 0 [clear] or 1 [minimal psoriasis]) were randomly reassigned to receive placebo, 80 mg of ixekizumab every 4 weeks, or 80 mg of ixekizumab every 12 weeks through week 60. Coprimary end points were the percentage of patients who had a score on the sPGA of 0 or 1 and a 75% or greater reduction from baseline in Psoriasis Area and Severity Index (PASI 75) at week 12. RESULTS In the UNCOVER-1 trial, at week 12, the patients had better responses to ixekizumab than to placebo; in the 2-wk dosing group, 81.8% had an sPGA score of 0 or 1 and 89.1% had a PASI 75 response; in the 4-wk dosing group, the respective rates were 76.4% and 82.6%; and in the placebo group, the rates were 3.2% and 3.9% (P<0.001 for all comparisons of ixekizumab with placebo). In the UNCOVER-1 and UNCOVER-2 trials, among the patients who were randomly reassigned at week 12 to receive 80 mg of ixekizumab every 4 weeks, 80 mg of ixekizumab every 12 weeks, or placebo, an sPGA score of 0 or 1 was maintained by 73.8%, 39.0%, and 7.0% of the patients, respectively. Patients in the UNCOVER-3 trial received continuous treatment of ixekizumab from weeks 0 through 60, and at week 60, at least 73% had an sPGA score of 0 or 1 and at least 80% had a PASI 75 response. Adverse events reported during ixekizumab use included neutropenia, candidal infections, and inflammatory bowel disease. CONCLUSIONS In three phase 3 trials involving patients with psoriasis, ixekizumab was effective through 60 weeks of treatment. As with any treatment, the benefits need to be weighed against the risks of adverse events. The efficacy and safety of ixekizumab beyond 60 weeks of treatment are not yet known

Large-scale forest inventories of the United States and China reveal positive effects of biodiversity on productivity

Background With the loss of species worldwide due to anthropogenic factors, especially in forested ecosystems, it has become more urgent than ever to understand the biodiversity-ecosystem functioning relationship (BEFR). BEFR research in forested ecosystems is very limited and thus studies that incorporate greater geographic coverage and structural complexity are needed. Methods We compiled ground-measured data from approx. one half million forest inventory sample plots across the contiguous United States, Alaska, and northeastern China to map tree species richness, forest stocking, and productivity at a continental scale. Based on these data, we investigated the relationship between forest productivity and tree species diversity, using a multiple regression analysis and a non-parametric approach to account for spatial autocorrelation. Results In general, forests in the eastern United States consisted of more tree species than any other regions in the country. The highest forest stocking values over the entire study area were concentrated in the western United States and Central Appalachia. Overall, 96.4 % of sample plots (477,281) showed a significant positive effect of species richness on site productivity, and only 3.6 % (17,349) had an insignificant or negative effect. Conclusions The large number of ground-measured plots, as well as the magnitude of geographic scale, rendered overwhelming evidence in support of a positive BEFR. This empirical evidence provides insights to forest management and biological conservation across different types of forested ecosystems. Forest timber productivity may be impaired by the loss of species in forests, and biological conservation, due to its potential benefits on maintaining species richness and productivity, can have profound impacts on the functioning and services of forested ecosystems

Evidence of innate lymphoid cell redundancy in humans

International audienceInnate lymphoid cells (ILCs) have potent immunological functions in experimental conditions in mice, but their contributions to immunity in natural conditions in humans have remained unclear. We investigated the presence of ILCs in a cohort of patients with severe combined immunodeficiency (SCID). All ILC subsets were absent in patients with SCID who had mutation of the gene encoding the common γ-chain cytokine receptor subunit IL-2Rγ or the gene encoding the tyrosine kinase JAK3. T cell reconstitution was observed in patients with SCID after hematopoietic stem cell transplantation (HSCT), but the patients still had considerably fewer ILCs in the absence of myeloablation than did healthy control subjects, with the exception of rare cases of reconstitution of the ILC1 subset of ILCs. Notably, the ILC deficiencies observed were not associated with any particular susceptibility to disease, with follow-up extending from 7 years to 39 years after HSCT. We thus report here selective ILC deficiency in humans and show that ILCs might be dispensable in natural conditions, if T cells are present and B cell function is preserved